The analysis performed according to the tumor stage by the random application of either the straight or spiraled wire type demonstrated that both anti-EpCAM-antibody- and anti-EpCAM/MUC1-antibody-covered CellCollectors could capture CTCs in different types of renal carcinoma Additional functionalization with the MUC1 antibody can help to characterize patients, classify tumors as low- or high-risk and monitor therapeutic responses. Here, EPCAM is linked to neoplasm.